Zhejiang Huahai Pharmaceutical Co., Ltd.June 28, 2019

FDA 483 - Zhejiang Huahai Pharmaceutical Co., Ltd. - June 28, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Huahai Pharmaceutical Co., Ltd.

Record Details

Zhejiang Huahai Pharmaceutical Co. Ltd. in Linhai, China, an API and drug product manufacturer, was cited for significant deficiencies in its quality systems. Observations included incomplete investigations into product discrepancies, inadequate procedures for preventing microbiological contamination in sterile products, and failures in its change control system. The firm also had deficient master production records and laboratory control specifications.

Company: Zhejiang Huahai Pharmaceutical Co., Ltd.
Inspection Date: June 28, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Jonathan W. Chapman (investigator)

Open in Dashboard

ID · 90a0c6c6-2a30-43db-ab08-8293a7514d58